Episode Details
Back to Episodes
Pharmaceutical Executive Daily: FDA Issues CRL to AbbVie
Published 3 weeks, 5 days ago
Description
In today’s Pharmaceutical Executive Daily, the FDA issues a complete response letter to AbbVie for a biologics license application, Regeneron moves to lower patient costs tied to its newly approved gene therapy, and the FDA approves Otarmeni for OTOF-related hearing loss.